Tagged Articles

overweight 27 articles

Advocates push for more aggressive approach to gestational diabetes

A change in the way pregnant women are tested for gestation diabetes could greatly increase the number of women diagnosed with the disease, which may help keep both mother and baby healthier in the future. Gestational diabetes is a form of the disease that either starts or is first diagnosed during pregnancy. It is a growing problem, as more women are waiting until their 30s or 40s to have babies, and more women are overweight before they become pregnant. It is one of the most common complications of pregnancy. Almost all pregnant women are checked for gestational diabetes because if ... Read More

European drug advisors reject Qsiva (Qsymia) diet drug based on safety concerns

Advisors for the European Union’s health agency has again recommended against approving the new weight loss drug Qsiva, made by Vivus Inc. The Committee for Medicinal Products for Human Use raised concerns about the cardiovascular safety of the drug, saying it would need more data proving its safety before it would reconsider its rejection. Qsiva is a combination of two FDA-approved drugs – phentermine, an appetite suppressant, and topiramate, used to treat epilepsy and migraines. Phentermine was part of the fen-phen diet drug cocktail that was popular in the 1990s, but was pulled from the market after studies showed the ... Read More

AAP issues first-ever guidelines for type 2 diabetes in children, teens

The American Academy of Pediatrics (AAP) has issued the first guidelines for the management of type 2 diabetes in children and teenagers aged 10 to 18. The guidelines were developed to assist pediatricians and pediatric endocrinologists, who most often are used to dealing with type 1 diabetes. However, the increase in childhood obesity has led to more children being diagnosed with type 2 diabetes – a condition once thought to affect adults only. Now, as many as one in three children diagnosed with diabetes has type 2. It can be difficult to quickly distinguish between type 1 and type 2 diabetes in ... Read More

European regulators skeptical about new prescription diet pills

European drug regulators are leery about approving the new weight loss drug Belviq because of safety concerns, including heart valve problems and psychiatric side effects in patients, and tumors observed during studies on lab rats. Belviq is currently under review by an advisory panel for the European Medicines Agency (EMA), which is expected to make a recommendation for the EMA by March whether to approve the drug. Arena Pharmaceuticals, the drug’s maker, has been working with the agency to answer questions and clear up any matters that stand in the way of approval. But its chances may be slim. The ... Read More

Diet pill Qsymia sales sluggish but analysts say pill has blockbuster potential

About 14,500 people have filled prescriptions for the new diet pill Qsymia since it hit the market in September, and the number of prescriptions are growing each month. Qsymia became the first weight loss pill to be sold in the U.S. since 1999. It is intended to be a lifelong treatment to help overweight and obese people manage their weight. Qysmia is a combination phentermine, a stimulant that acts as an appetite suppressant, and topiramate, a drug used to treat seizures. Analysts speculate that it could become blockbuster drug within a few years, generating sales of $1 billion or more. ... Read More

‘Lifestyle intervention’ for weight loss does not improve heart attack risk in diabetics

Longtime type 2 diabetics who undergo “lifestyle intervention” and lose weight do not reduce their heart attack and stroke risk, suggests a new study supported by the National Institutes of Health. The study focused on whether an intensive diet and exercise program resulting in weight loss would reduce the rates of heart disease, stroke, and cardiovascular-related deaths in overweight and obese people with type 2 diabetes. This demographic is already at greater risk for these conditions. For the study, researchers worked with more than 5,000 people. Half of the participants engaged in an intensive diet and exercise program while the ... Read More

New diet drug Qsymia may be rejected by European drug regulators

Qsymia, first diet drug to be approved in 13 years by the U.S. Food and Drug Administration (FDA), may not get clearance from the European Medicines Agency because of the potential for heart problems. A European Union advisory panel is expected to rule on the weight loss treatment sometime next month, but the drug’s maker Vivus Inc. says it has been getting some cold vibes from the group. If rejected, Vivus says it will file a new marketing application or appeal the decision. Vivus wants to market Qsymia in Europe under the name Qsiva. This summer, the FDA approved Qsymia ... Read More

Study: Antibiotics may make babies chubby

Babies who are treated with antibiotics before 6 months of age are more likely to be chubby, according to a new study published this week in the International Journal of Obesity. Researchers say that exposure to antibiotics, especially early in life, may kill off healthy bacteria in the intestines that affect how our cells absorb nutrients. Preliminary studies have already linked changes in these microbial cells to obesity, inflammatory bowel disease, asthma, and other conditions. Yet, direct causal proof has not been found. This new study was the first to analyze the relationship between use of antibiotics and body mass ... Read More

Normal weight type 2 diabetics more likely to die from disease than overweight, obese diabetics

Normal-weight people with type 2 diabetes are twice as likely to die from the disease than overweight or obese people with type 2 diabetes, according to a new study recently published in the Journal of the American Medical Association. The study compared death rates among 2,625 type 2 diabetics aged 40 and older, and found that the death rate among normal-weight diabetics was 284.8 per 10,000 person-years compared to 152.1 per 10,000 person-years in overweight or obese diabetics. They also found that older adults and non-white participants were more likely to develop type 2 diabetes at a normal weight. Researchers ... Read More

FDA approves Belviq, first weight loss drug in more than a decade

A new prescription weight-loss pill has been approved by the Food and Drug Administration (FDA), making it the first diet pill to hit the U.S. market in more than a decade. Arena Pharmaceuticals Belviq (lorcasserin) was deemed safe enough to get a nod by drug regulators, though the agency says studies showed only modest weight loss in clinical trials. Belviq was approved for adults who are obese or overweight with at least one medical complication such as diabetes or high cholesterol. The drug should be used with a healthy diet and exercise. The FDA first rejected Belviq in 2010 after ... Read More